squibb – Page 4

Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions

FDA Approves Adagrasib (Krazati) with Cetuximab for KRAS G12C-Mutated Colorectal Cancer

10 months ago talkbio0Tagged adagrasib, amgen, Approved, cetuximab, Colorectal Carcinoma, G12C, K-ras Oncogene, KRAZATI, Lumakras, Myers, squibb, United States Food and Drug Administration

Adagrasib, Krazati, Cetuximab, KRAS G12C, Colorectal Cancer, FDA Approval, Bristol Myers Squibb, Mirati Therapeutics, Amgen, Lumakras

BMS’s KRAS Inhibitor Krazati Receives FDA Approval for Colorectal Cancer Treatment

10 months ago talkbio0Tagged adagrasib, Approved, cetuximab, Colorectal Carcinoma, Inhibitor, K-ras Oncogene, KRAZATI, Myers, squibb, United States Food and Drug Administration

Krazati, Bristol Myers Squibb, FDA approval, colorectal cancer, KRAS inhibitor, adagrasib, cetuximab

Bristol Myers Squibb to Cut Over 860 Jobs in New Jersey as Part of $1.5 Billion Savings Campaign

11 months ago talkbio0Tagged Drug Industry, Financial cost, Financial savings, Myers, New Jersey, savings campaign, squibb

Bristol Myers Squibb, job cuts, New Jersey, $1.5 billion savings campaign, cost savings, pharmaceutical industry

Bristol Myers’ KRAS Confirmatory Data Avoid Amgen’s Flaws but Leave FDA Prospect Unclear

11 months ago talkbio0Tagged Accelerated, amgen, approval pathway, clinical benefits, confirmatory data, confirmatory trials, K-ras Oncogene, Myers, oncology therapies, squibb, United States Food and Drug Administration

Bristol Myers Squibb, KRAS confirmatory data, Amgen, FDA, accelerated approval pathway, oncology therapies, clinical benefits, confirmatory trials

RayzeBio Warned of Potential Actinium Isotope Supply Issues Before $4.1B BMS Deal

11 months ago talkbio0Tagged actinium-225, Isotope Supply, Myers, Neoplasms, Neurosecretory Systems, Radiopharmaceuticals, RayzeBio, squibb

RayzeBio, Bristol Myers Squibb, Actinium-225, Isotope Supply Issues, Radiopharmaceuticals, Neuroendocrine Tumors